結核病藥物市場規模、份額和趨勢分析報告：按疾病類型（活動性結核病、潛伏性結核病）、治療方法、給藥途徑、製劑、分銷渠道、地區、細分市場預測，2023 ～ 2030 年

結核病藥物市場的增長和趨勢

根據 Grand View Research, Inc. 的最新報告，2023 年至 2030 年全球結核病藥物市場規模將達到 29.9 億美元，複合年增長率為 5.09%。結核病藥物的需求預計將受結核病流行率上升的驅動。

根據世界衛生組織的《2022 年全球結核病報告》，估計 2021 年將有 1060 萬人受此影響，比 2020 年增長 4.5%，約有 160 萬人死亡。 這種高死亡率表明市場上對具有成本效益和高效的藥物的需求未得到滿足。

從 2020 年到 2021 年，耐藥結核病 (DR-TB) 的負擔增加了 3%，2021 年新增 450,000 例利福平耐藥結核病病例。 這是多年來第一次報告患有結核病和耐藥結核病的人數有所增加。 2021 年 COVID-19 大流行擾亂了許多服務，包括結核病護理。 然而，它的影響在結核病應對中受到嚴重影響。 此外，目前稱為 BCG 的疫苗已有 100 多年曆史，對成人的療效有限，限制了其控制感染的能力。 因此，治療劑存在商機。

耐多藥和廣泛耐藥結核病的發病率不斷上升，進一步推動了對提供適當療法的需求。 2022 年 12 月，世衛組織發布了更新後的綜合指南，其中顯著改進了耐藥結核病的治療。 該指南總結並推薦使用一種新的 6 個月口服方案 (BPaLM)，該方案由普托馬尼、貝達奎林、莫西沙星和利奈唑胺組成，用於治療 MDR/RR-TB 患者。 BPaLM 方案有望縮短治療時間並帶來更好的結果。

此外，各大公司都專注於聯合研究和合作，以開發新型結核病藥物並保持市場競爭力。 例如，2021 年 7 月，一個由來自 13 個國家的 30 個合作夥伴組成的新聯盟正式成立，以推進結核病藥物的發展。 該項目是 UNITE4TB，這是一項投資約 1.98 億美元的七年計劃，旨在加速和改進治療方法。 此外，諸如 Ni-kshay Mitra 等於 2022 年 9 月啟動的計劃正在興起，目的是到 2025 年底在印度終結並針對結核病。

結核病藥物市場報告要點。

• 到 2022 年，由於患病率和復發率增加，活動性結核病將成為主流。
• 由於需求不斷增加以及為開發新的二線療法而加大的研發力度，預計二線療法部分在預測期內將呈現最快的增長速度。
• 到 2022 年，由於有許多片劑形式的藥物可供使用，口服製劑將主導市場。
• 由於治療資金減少和疾病診斷率降低，COVID-19 大流行對市場產生了負面影響。
• 到 2022 年，MEA 將佔據最大的市場份額。 這是由於加大了對疾病的早期診斷的努力和增加了治療的採用。

內容

第 1 章結核病藥物市場：研究方法和範圍

• 市場細分
  • 細分範圍
  • 區域範圍
• 調查方法
• 信息採購
  • 購買的數據庫
  • GVR 內部數據庫
  • 次要信息
  • 初步調查
  • 初步調查的詳細信息
• 信息或數據分析
  • 數據分析模型
• 市場製定和驗證
• 模型詳細信息
  • 商品流分析
    • 方法 1：商品流方法
    • 方法 2：使用自下而上的方法按國家/地區進行市場預測
    • 方法 2：使用自上而下的方法逐個國家/地區進行市場估算
• 全球市場：CAGR 計算
• 次要信息列表
• 目的
• 縮寫列表

第 2 章結核病藥物市場：執行摘要

• 市場概況
• 片段快照
• 競爭格局快照

第 3 章結核病藥物市場：行業展望

• 市場系列展望
  • 母市場沿襲預測
  • 相關/子公司市場前景
• 描繪滲透率和增長前景
• 市場動態
  • 市場驅動力
    • 結核病患病率上升
    • 增加對醫療保健基礎設施的投資
    • 不斷增長的老年人口
  • 市場製約因素分析
    • 耐多藥結核病的高昂費用
    • 與抗結核藥物相關的副作用
• SWOT 分析，按因素（政治和法律、經濟和技術）
• 行業分析 - 搬運工
• 報銷和監管場景
• 主要交易和戰略聯盟
  • 新產品發布
  • 得到
  • 分機
  • 夥伴關係
  • 營銷和推廣

第 4 章結核病藥物市場：競爭格局

• 近期發展和影響分析：主要市場進入者
  • 安索夫矩陣
• 公司分類
  • 創新者
    • 市場差異化因素
• 供應商情況
  • 主要分銷商和渠道合作夥伴列表
  • 主要客戶
  • 2022 年主要參與者的市場份額分析
• 上市公司
  • 競爭儀錶盤分析
• 私人公司
  • 主要初創企業名單
• 本地網絡地圖

第 5 章結核病藥物市場：疾病類型的業務分析

• 定義和範圍
• 2022 年和 2030 年按疾病類型劃分的市場份額分析
• 2018-2030 年按疾病類型劃分的全球結核病藥物市場
• 結核病藥物市場：疾病類型的變化分析
• 活動性肺結核
• 潛伏性肺結核

第 6 章結核病藥物市場：治療業務分析

• 定義和範圍
• 2022 年和 2030 年治療市場份額分析
• 2018-2030 年全球治療結核病藥物市場
• 結核病治療市場：治療波動分析
• 一線治療
• 二級治療

第 7 章結核病藥物市場：給藥途徑業務分析

• 定義和範圍
• 2022 年和 2030 年行政程序市場份額分析
• 全球結核病藥物市場，按給藥途徑，2018-2030 年
• 結核病治療市場：給藥途徑的變化分析
• 口語
• 家長
• 其他

第 8 章結核病藥物市場：劑型業務分析

• 定義和範圍
• 劑型市場份額分析，2022 年和 2030 年
• 全球結核病藥物市場，按配方，2018-2030 年
• 結核病藥物市場：配方變化分析
• 藥丸
• 膠囊
• 注射
• 其他

第 9 章結核病藥物市場：分銷渠道的業務分析

• 定義和範圍
• 2022 年和 2030 年分銷渠道市場份額分析
• 全球結核病藥物市場，按分銷渠道，2018-2030 年
• 結核病藥物市場：分銷渠道波動分析
• 醫院藥房
• 零售藥房
• 在線藥店
• 其他

第 10 章結核病藥物市場：區域業務分析

• 定義和範圍
• 2022 年和 2030 年區域市場份額分析
• 區域市場儀表板
• 區域市場概況
• SWOT 分析，按因素（政治和法律、經濟和技術）
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 母馬
• 2022-2030 年市場規模、預測、趨勢分析
• 北美
  • 美國
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入場景
    • 投資場景
  • 加拿大
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 進出口方案
    • 投資場景
• 歐洲
  • 英國
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入場景
    • 投資場景
  • 德國
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入場景
    • 投資場景
  • 西班牙
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 進出口方案
    • 投資場景
  • 法國
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 進出口方案
    • 投資場景
  • 意大利
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 進出口方案
    • 投資場景
  • 俄羅斯
    • 監管框架
    • 競爭場景
    • 導出和導入方案
    • 投資場景
  • 丹麥
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入場景
    • 投資場景
  • 瑞典
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入方案
    • 投資場景
  • 挪威
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入方案
    • 投資場景
• 亞太地區
  • 日本
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入方案
    • 投資場景
  • 中國
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 進出口方案
    • 投資場景
  • 印度
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 進出口方案
    • 投資場景
  • 韓國
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入方案
    • 投資場景
  • 泰國
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入方案
    • 投資場景
  • 澳大利亞
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入場景
    • 投資場景
• 拉丁美洲
  • 巴西
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入場景
    • 投資場景
  • 墨西哥
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入場景
    • 投資場景
  • 阿根廷
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入方案
    • 投資場景
• 多邊環境協定
  • 南非
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入方案
    • 投資場景
  • 沙特阿拉伯
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入場景
    • 投資場景
  • 阿拉伯聯合酋長國
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入場景
    • 投資場景
  • 科威特
    • 主要國家動態
    • 監管框架
    • 競爭場景
    • 導出和導入場景
    • 投資場景

第 11 章結核病藥物市場：公司概況

• 公司簡介
  • 阿斯利康
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • 強生服務公司
    • 公司簡介
  • 2.財務業績
    • 產品基準
    • 戰略舉措
  • 禮來公司
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • F. Hoffmann-La Roche Ltd.
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Viatris Inc.（Mylan NV）
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • 梯瓦製藥工業有限公司
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • 賽諾菲
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • 諾華公司
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • 太陽製藥工業有限公司
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • 輝瑞公司
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措

Tuberculosis Therapeutics Market Growth & Trends:

The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030, according to a new report by Grand View Research, Inc., The demand for TB therapeutics is attributable to the rising prevalence of tuberculosis. According to the World Health Organization's 2022 Global TB report, an estimated 10.6 million people suffered in 2021, a 4.5% increase from 2020, and has accounted for the death of around 1.6 million people. This high rate of mortality demonstrates an unmet need for cost-effective and efficient drugs in the market.

The burden of drug-resistant tuberculosis (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant tuberculosis in 2021. This is the first time in past few years that an increase in the number of people suffering from TB and DR-TB has been reported. The COVID-19 pandemic in 2021 has disrupted many services, including TB care. However, the impact has been severely seen in the TB response. Moreover, because the current vaccine, known as BCG, is over 100 years old and has limited efficacy in adults, the ability to control transmission is limited. Thus, creating business opportunity for therapeutics.

The rising incidence of multidrug-resistant and extensively drug-resistant tuberculosis has further propelled the demand for providing appropriate therapeutics. In December 2022 , the WHO released an updated consolidated guideline featuring major improvements on the treatment of drug-resistant TB. The guideline summarizes and recommends the use of a novel all-oral 6-month regimen consisting of pretomanid, bedaquiline, moxifloxacin, and linezolid (BPaLM) for treatment of patients suffering from MDR/RR-TB. The BPaLM regimen is expected to shorten the duration and offer better outcome of treatment.

Furthermore, key players are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market. For instance, in July 2021 , to advance tuberculosis therapeutics a new consortium of 30 partners from 13 countries has officially launched. The project is UNITE4TB and is a 7-year plan with an investment of around USD 198 million with a goal to accelerate and improve therapeutics. Moreover, initiatives such as the Ni-kshay Mitra launched in September 2022, have come up in India intending to eliminate and target tuberculosis by the end of 2025.

Tuberculosis Therapeutics Market Report Highlights:

• Active TB segment dominated et in 2022 and is attributable to the increasing prevalence and recurrence of condition

• Second line therapy segment is expected to show fastest growth rate over the forecast period owing to increasing demand and the rising research and development for development of newer second-line therapy drugs

• Oral segment dominated the market in 2022 attributable to the availability of a large number of drugs in form of tablets.

• The COVID-19 pandemic influenced the market adversely attributable to the reduced funding for therapeutics and decline in diagnosis rate of disease.

• MEA held the largest market share in 2022 which can be attributed to the enhanced focus on early diagnosis of the disease and improvement in adoption rate of treatments.

Table of Contents

Chapter 1 Tuberculosis Therapeutics Market: Methodology And Scope

• 1.1 Market Segmentation
  • 1.1.1 Segment Scope
  • 1.1.2 Regional Scope
  • 1.1.3 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
    • 1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
• 1.7 Global Market: Cagr Calculation
• 1.8 List Of Secondary Sources
• 1.9 Objectives
  • 1.9.1 Objective 1
  • 1.9.2 Objective 2
• 1.11 List of Abbreviations

Chapter 2 Tuberculosis Therapeutics Market: Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Tuberculosis Therapeutics Market: Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Lineage Outlook
  • 3.1.2 Related/Ancillary Market Outlook
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Market Dynamics
  • 3.3.1 Market Drivers
    • 3.3.1.1 Rise in the prevalence of tuberculosis
    • 3.3.1.2 Increasing investment for healthcare infrastructure
    • 3.3.1.3 Growing number of geriatric population
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 High cost of multidrug-resistant TB
    • 3.3.2.2 Side effects linked with anti-tuberculosis drugs
• 3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• 3.5 Industry Analysis - Porter's
• 3.6 Reimbursement & Regulatory Scenario
• 3.7 Major Deals & Strategic Alliances
  • 3.7.1 New Product Launch
  • 3.7.2 Acquisition
  • 3.7.3 Expansion
  • 3.7.4 Partnerships
  • 3.7.5 Marketing & Promotions

Chapter 4 Tuberculosis Therapeutics Market: Competitive Landscape

• 4.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 4.1.1 Ansoff Matrix
• 4.2 Company Categorization
  • 4.2.1 Innovators
    • 4.2.1.1 Market Differentiators
• 4.3 Vendor Landscape
  • 4.3.1 List Of Key Distributors And Channel Partners
  • 4.3.2 Key Customers
  • 4.3.3 Key Company Market Share Analysis, 2022
• 4.4 Public Companies
  • 4.4.1 Competitive Dashboard Analysis
• 4.5 Private Companies
  • 4.5.1 List Of Key Emerging Companies
• 4.6 Regional Network Map

Chapter 5 Tuberculosis Therapeutics Market: Disease Type Business Analysis

• 5.1 Definition And Scope
• 5.2 Disease Type Market Share Analysis, 2022 & 2030
• 5.3 Global Tuberculosis Therapeutics Market, By Disease Type, 2018 To 2030
• 5.4 Tuberculosis Therapeutics Market: Disease Type Movement Analysis
• 5.5 Active Tb
  • 5.5.1 Active Tb Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.6 Latent Tb
  • 5.6.1 Latent Tb Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Tuberculosis Therapeutics Market: Therapy Business Analysis

• 6.1 Definition and Scope
• 6.2 Therapy Market Share Analysis, 2022 & 2030
• 6.3 Global Tuberculosis Therapeutics Market, By Therapy, 2018 To 2030
• 6.4 Tuberculosis Therapeutics Market: Therapy Movement Analysis
• 6.5 First-Line Therapy
  • 6.5.1 First-Line Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.6 Second-Line Therapy
  • 6.6.1 Second-Line Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Tuberculosis Therapeutics Market: Route of Administration Business Analysis

• 7.1 Definition and Scope
• 7.2 Route of Administration Market Share Analysis, 2022 & 2030
• 7.3 Global Tuberculosis Therapeutics Market, By Route of Administration, 2018 To 2030
• 7.4 Tuberculosis Therapeutics Market: Route of Administration Movement Analysis
• 7.5 Oral
  • 7.5.1 Oral Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.6 Parentral
  • 7.6.1 Parentral Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.7 Others
  • 7.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 Tuberculosis Therapeutics Market: Dosage Form Business Analysis

• 8.1 Definition and Scope
• 8.2 Dosage Form Market Share Analysis, 2022 & 2030
• 8.3 Global Tuberculosis Therapeutics Market, By Dosage Form, 2018 To 2030
• 8.4 Tuberculosis Therapeutics Market: Dosage Form Movement Analysis
• 8.5 Tablets
  • 8.5.1 Tablets Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.6 Capsules
  • 8.6.1 Capsules Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.7 Injections
  • 8.7.1 Injections Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.8 Others
  • 8.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9 Tuberculosis Therapeutics Market: Distribution Channel Business Analysis

• 9.1 Definition and Scope
• 9.2 Distribution Channel Market Share Analysis, 2022 & 2030
• 9.3 Global Tuberculosis Therapeutics Market, By Distribution Channel, 2018 To 2030
• 9.4 Tuberculosis Therapeutics Market: Distribution Channel Movement Analysis
• 9.5 Hospital Pharmacy
  • 9.5.1 Hospital Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.6 Retail Pharmacy
  • 9.6.1 Reatail Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.7 Online Pharmacy
  • 9.7.1 Online Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.8 Others
  • 9.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 10 Tuberculosis Therapeutics Market: Regional Business Analysis

• 10.1 Definition & Scope
• 10.2 Regional Market Share Analysis, 2022 & 2030
• 10.3 Regional Market Dashboard
• 10.4 Regional Market Snapshot
• 10.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
  • 10.5.1 North America
  • 10.5.2 Europe
  • 10.5.3 Asia Pacific
  • 10.5.4 Latin America
  • 10.5.5 Mea
• 10.6 Market Size, & Forecasts, Trend Analysis, 2022 to 2030
• 10.7 North America
  • 10.7.1 North America Tuberculosis Therapeutics Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 10.7.2 U.S.
    • 10.7.2.1 U.S. Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.7.2.2 Key Country Dynamics
    • 10.7.2.3 Regulatory Framework
    • 10.7.2.4 Competitive Scenario
    • 10.7.2.5 Import Export Scenario
    • 10.7.2.6 Investments Scenario
  • 10.7.3 Canada
    • 10.7.3.1 Canada tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.7.3.2 Key Country Dynamics
    • 10.7.3.3 Regulatory Framework
    • 10.7.3.4 Competitive Scenario
    • 10.7.3.5 Import Export Scenario
    • 10.7.3.6 Investments Scenario
• 10.8 Europe
  • 10.8.1 Europe Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.8.2 U.K.
    • 10.8.2.1 U.K. Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.2.2 Key Country Dynamics
    • 10.8.2.3 Regulatory Framework
    • 10.8.2.4 Competitive Scenario
    • 10.8.2.5 Import Export Scenario
    • 10.8.2.6 Investments Scenario
  • 10.8.3 Germany
    • 10.8.3.1 Germany Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.3.2 Key Country Dynamics
    • 10.8.3.3 Regulatory Framework
    • 10.8.3.4 Competitive Scenario
    • 10.8.3.5 Import Export Scenario
    • 10.8.3.6 Investments Scenario
  • 10.8.4 Spain
    • 10.8.4.1 Spain tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.4.2 Key Country Dynamics
    • 10.8.4.3 Regulatory Framework
    • 10.8.4.4 Competitive Scenario
    • 10.8.4.5 Import Export Scenario
    • 10.8.4.6 Investments Scenario
  • 10.8.5 France
    • 10.8.5.1 France tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.5.2 Key Country Dynamics
    • 10.8.5.3 Regulatory Framework
    • 10.8.5.4 Competitive Scenario
    • 10.8.5.5 Import Export Scenario
    • 10.8.5.6 Investments Scenario
  • 10.8.6 Italy
    • 10.8.6.1 Italy tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.6.2 Key Country Dynamics
    • 10.8.6.3 Regulatory Framework
    • 10.8.6.4 Competitive Scenario
    • 10.8.6.5 Import Export Scenario
    • 10.8.6.6 Investments Scenario
  • 10.8.7 Russia
    • 10.8.7.1 Russia tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.7.3 Regulatory Framework
    • 10.8.7.4 Competitive Scenario
    • 10.8.7.5 Import Export Scenario
    • 10.8.7.6 Investments Scenario
  • 10.8.8 Denmark
    • 10.8.8.1 Denmark Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.8.2 Key Country Dynamics
    • 10.8.8.3 Regulatory Framework
    • 10.8.8.4 Competitive Scenario
    • 10.8.8.5 Import Export Scenario
    • 10.8.8.6 Investments Scenario
  • 10.8.9 Sweden
    • 10.8.9.1 Sweden Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.9.2 Key Country Dynamics
    • 10.8.9.3 Regulatory Framework
    • 10.8.9.4 Competitive Scenario
    • 10.8.9.5 Import Export Scenario
    • 10.8.9.6 Investments Scenario
  • 10.8.10 Norway
    • 10.8.10.1 Norway Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.10.2 Key Country Dynamics
    • 10.8.10.3 Regulatory Framework
    • 10.8.10.4 Competitive Scenario
    • 10.8.10.5 Import Export Scenario
    • 10.8.10.6 Investments Scenario
• 10.9 Asia Pacific
  • 10.9.1 Asia-Pacific Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.9.2 Japan
    • 10.9.2.1 Japan Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.2.2 Key Country Dynamics
    • 10.9.2.3 Regulatory Framework
    • 10.9.2.4 Competitive Scenario
    • 10.9.2.5 Import Export Scenario
    • 10.9.2.6 Investments Scenario
  • 10.9.3 China
    • 10.9.3.1 China Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.3.2 Key Country Dynamics
    • 10.9.3.3 Regulatory Framework
    • 10.9.3.4 Competitive Scenario
    • 10.9.3.5 Import Export Scenario
    • 10.9.3.6 Investments Scenario
  • 10.9.4 India
    • 10.9.4.1 India Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.4.2 Key Country Dynamics
    • 10.9.4.3 Regulatory Framework
    • 10.9.4.4 Competitive Scenario
    • 10.9.4.5 Import Export Scenario
    • 10.9.4.6 Investments Scenario
  • 10.9.5 South Korea
    • 10.9.5.1 South Korea Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.5.2 Key Country Dynamics
    • 10.9.5.3 Regulatory Framework
    • 10.9.5.4 Competitive Scenario
    • 10.9.5.5 Import Export Scenario
    • 10.9.5.6 Investments Scenario
  • 10.9.6 Thailand
    • 10.9.6.1 Thailand Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.6.2 Key Country Dynamics
    • 10.9.6.3 Regulatory Framework
    • 10.9.6.4 Competitive Scenario
    • 10.9.6.5 Import Export Scenario
    • 10.9.6.6 Investments Scenario
  • 10.9.7 Australia
    • 10.9.7.1 Australia tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.9.7.2 Key Country Dynamics
    • 10.9.7.3 Regulatory Framework
    • 10.9.7.4 Competitive Scenario
    • 10.9.7.5 Import Export Scenario
    • 10.9.7.6 Investments Scenario
• 10.10 Latin America
  • 10.10.1 Latin America Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.10.2 Brazil
    • 10.10.2.1 Brazil Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.10.2.2 Key Country Dynamics
    • 10.10.2.3 Regulatory Framework
    • 10.10.2.4 Competitive Scenario
    • 10.10.2.5 Import Export Scenario
    • 10.10.2.6 Investments Scenario
  • 10.10.3 Mexico
    • 10.10.3.1 Mexico Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.10.3.2 Key Country Dynamics
    • 10.10.3.3 Regulatory Framework
    • 10.10.3.4 Competitive Scenario
    • 10.10.3.5 Import Export Scenario
    • 10.10.3.6 Investments Scenario
  • 10.10.4 Argentina
    • 10.10.4.1 Argentina Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.10.4.2 Key Country Dynamics
    • 10.10.4.3 Regulatory Framework
    • 10.10.4.4 Competitive Scenario
    • 10.10.4.5 Import Export Scenario
    • 10.10.4.6 Investments Scenario
• 10.11 MEA
  • 10.11.1 MEA Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.11.2 South Africa
    • 10.11.2.1 South Africa Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.2.2 Key Country Dynamics
    • 10.11.2.3 Regulatory Framework
    • 10.11.2.4 Competitive Scenario
    • 10.11.2.5 Import Export Scenario
    • 10.11.2.6 Investments Scenario
  • 10.11.3 Saudi Arabia
    • 10.11.3.1 Saudi Arabia Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.3.2 Key Country Dynamics
    • 10.11.3.3 Regulatory Framework
    • 10.11.3.4 Competitive Scenario
    • 10.11.3.5 Import Export Scenario
    • 10.11.3.6 Investments Scenario
  • 10.11.4 UAE
    • 10.11.4.1 UAE Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.4.2 Key Country Dynamics
    • 10.11.4.3 Regulatory Framework
    • 10.11.4.4 Competitive Scenario
    • 10.11.4.5 Import Export Scenario
    • 10.11.4.6 Investments Scenario
  • 10.11.5 Kuwait
    • 10.11.5.1 Kuwait Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.5.2 Key Country Dynamics
    • 10.11.5.3 Regulatory Framework
    • 10.11.5.4 Competitive Scenario
    • 10.11.5.5 Import Export Scenario
    • 10.11.5.6 Investments Scenario

Chapter 11 Tuberculosis Therapeutics Market: Company Profiling

• 11.1 Company Profiles
  • 11.1.1 Astrazeneca
    • 11.1.1.1 Company Overview
    • 11.1.1.2 Financial Performance
    • 11.1.1.3 Product Benchmarking
    • 11.1.1.4 Strategic Initiatives
  • 11.1.2 Johnson & Johnson Services, Inc.
    • 11.1.2.1 Company Overview
  • 11.1.2 2.Financial Performance
    • 11.1.2.3 Product Benchmarking
    • 11.1.2.4 Strategic Initiatives
  • 11.1.3 Eli Lilly And Company
    • 11.1.3.1 Company Overview
    • 11.1.3.2 Financial Performance
    • 11.1.3.3 Product Benchmarking
    • 11.1.3.4 Strategic Initiatives
  • 11.1.4 F. Hoffmann-La Roche Ltd.
    • 11.1.4.1 Company Overview
    • 11.1.4.2 Financial Performance
    • 11.1.4.3 Product Benchmarking
    • 11.1.4.4 Strategic Initiatives
  • 11.1.5 Viatris Inc. (Mylan N.V.)
    • 11.1.5.1 Company Overview
    • 11.1.5.2 Financial Performance
    • 11.1.5.3 Product Benchmarking
    • 11.1.5.4 Strategic Initiatives
  • 11.1.6 Teva Pharmaceutical Industries, Ltd.
    • 11.1.6.1 Company Overview
    • 11.1.6.2 Financial Performance
    • 11.1.6.3 Product Benchmarking
    • 11.1.6.4 Strategic Initiatives
  • 11.1.7 Sanofi
    • 11.1.7.1 Company Overview
    • 11.1.7.2 Financial Performance
    • 11.1.7.3 Product Benchmarking
    • 11.1.7.4 Strategic Initiatives
  • 11.1.8 Novartis Ag
    • 11.1.8.1 Company Overview
    • 11.1.8.2 Financial Performance
    • 11.1.8.3 Product Benchmarking
    • 11.1.8.4 Strategic Initiatives
  • 11.1.9 Sun Pharmaceutical Industries Ltd.
    • 11.1.9.1 Company Overview
    • 11.1.9.2 Financial Performance
    • 11.1.9.3 Product Benchmarking
    • 11.1.9.4 Strategic Initiatives
  • 11.1.10 Pfizer Inc.
    • 11.1.10.1 Company Overview
    • 11.1.10.2 Financial Performance
    • 11.1.10.3 Product Benchmarking
    • 11.1.10.4 Strategic Initiatives

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 Incidence of Diseases
• Table 4 Global Tuberculosis Therapeutics Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Tuberculosis Therapeutics Market, By Drug type, 2018 - 2030 (USD Million)
• Table 6 North America Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 7 North America Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 8 North America Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 9 North America Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 10 North America Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 11 North America Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 U.S. Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 13 U.S. Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 14 U.S. Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 15 U.S. Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 16 U.S. Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 17 Canada Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 18 Canada Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 19 Canada Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 20 Canada Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 21 Canada Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 Europe Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 23 Europe Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 24 Europe Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 25 Europe Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 26 Europe Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 27 Europe Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 Germany Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 29 Germany Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 30 Germany Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 31 Germany Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 32 Germany Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 33 U.K. Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 34 U.K. Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 35 U.K. Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 36 U.K. Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 37 U.K. Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 France Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 39 France Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 40 France Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 41 France Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 42 France Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 Italy Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 44 Italy Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 45 Italy Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 46 Italy Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 47 Italy Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 48 Spain Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 49 Spain Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 50 Spain Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 51 Spain Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 52 Spain Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 Denmark Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 54 Denmark Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 55 Denmark Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 56 Denmark Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 57 Denmark Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 58 Sweden Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 59 Sweden Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 60 Sweden Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 61 Sweden Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 62 Sweden Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Norway Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 64 Norway Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 65 Norway Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 66 Norway Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 67 Norway Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 68 Asia Pacific Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 69 Asia Pacific Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 70 Asia Pacific Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 71 Asia Pacific Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 72 Asia Pacific Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 73 Asia Pacific Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 74 Japan Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 75 Japan Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 76 Japan Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 77 Japan Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 78 Japan Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 China Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 80 China Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 81 China Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 82 China Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 83 China Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 84 India Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 85 India Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 86 India Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 87 India Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 88 India Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 89 South Korea Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 90 South Korea Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 91 South Korea Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 92 South Korea Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 93 South Korea Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 94 Australia Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 95 Australia Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 96 Australia Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 97 Australia Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 98 Australia Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 99 Thailand Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 100 Thailand Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 101 Thailand Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 102 Thailand Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 103 Thailand Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 104 Latin America Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 105 Latin America Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 106 Latin America Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 107 Latin America Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 108 Latin America Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 109 Latin America Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 110 Brazil Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 111 Brazil Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 112 Brazil Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 113 Brazil Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 114 Brazil Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 115 Mexico Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 116 Mexico Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 117 Mexico Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 118 Mexico Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 119 Mexico Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 120 Argentina Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 121 Argentina Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 122 Argentina Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 123 Argentina Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 124 Argentina Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 125 Middle East & Africa Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 126 Middle East & Africa Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 127 Middle East & Africa Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 128 Middle East & Africa Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 129 Middle East & Africa Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 130 Middle East & Africa Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 131 Saudi Arabia Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 132 Saudi Arabia Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 133 Saudi Arabia Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 134 Saudi Arabia Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 135 Saudi Arabia Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 136 South Africa Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 137 South Africa Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 138 South Africa Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 139 South Africa Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 140 South Africa Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 141 UAE Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 142 UAE Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 143 UAE Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 144 UAE Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 145 UAE Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 146 Kuwait Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 147 Kuwait Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 148 Kuwait Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 149 Kuwait Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 150 Kuwait Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Tuberculosis Therapeutics Market Segmentation
• Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 11 Penetration & Growth Prospect Mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Market Penetration & Growth Prospect Mapping
• Fig. 15 Tuberculosis therapeutics market: Disease type outlook and key takeaways
• Fig. 16 Tuberculosis therapeutics market: Disease type movement analysis & market share 2022 & 2030
• Fig. 17 Active TB market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Latent TB market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Tuberculosis therapeutics market: Therapy outlook and key takeaways
• Fig. 20 Tuberculosis therapeutics market: Therapy movement analysis & market share 2022 & 2030
• Fig. 21 First-line therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Second-line therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Tuberculosis therapeutics market: Route of administration outlook and key takeaways
• Fig. 24 Tuberculosis therapeutics market: Route of administration movement analysis & market share 2022 & 2030
• Fig. 25 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Tuberculosis therapeutics market: Dosage form outlook and key takeaways
• Fig. 29 Tuberculosis therapeutics market: Dosage form movement analysis & market share 2022 & 2030
• Fig. 30 Tablets market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Capsules market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Injections market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Tuberculosis therapeutics market: Distribution channel outlook and key takeaways
• Fig. 35 Tuberculosis therapeutics market: Distribution channel movement analysis & market share 2022 & 2030
• Fig. 36 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Regional Marketplace: Key Takeaways
• Fig. 41 Regional Outlook, 2022 & 2030
• Fig. 42 Regional Market Dashboard
• Fig. 43 Regional Market Place: Key Takeaways
• Fig. 44 North America, SWOT Analysis
• Fig. 45 Europe, SWOT Analysis
• Fig. 46 Asia Pacific, SWOT Analysis
• Fig. 47 Latin America, SWOT Analysis
• Fig. 48 MEA, SWOT Analysis
• Fig. 49 North America
• Fig. 50 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 51 U.S.
• Fig. 52 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 53 Canada
• Fig. 54 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 55 Europe
• Fig. 56 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 57 U.K.
• Fig. 58 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 59 Germany
• Fig. 60 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 61 France
• Fig. 62 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 63 Italy
• Fig. 64 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 65 Spain
• Fig. 66 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 67 Denmark
• Fig. 68 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 69 Sweden
• Fig. 70 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 71 Norway
• Fig. 72 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 73 Asia Pacific
• Fig. 74 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 75 Japan
• Fig. 76 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 77 China
• Fig. 78 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 79 India
• Fig. 80 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 81 Australia
• Fig. 82 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 83 Thailand
• Fig. 84 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 85 South Korea
• Fig. 86 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 87 Latin America
• Fig. 88 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 89 Brazil
• Fig. 90 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 91 Mexico
• Fig. 92 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 93 Argentina
• Fig. 94 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 95 MEA
• Fig. 96 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 97 South Africa
• Fig. 98 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 99 Saudi Arabia
• Fig. 100 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 101 UAE
• Fig. 102 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 103 Kuwait
• Fig. 104 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 105 Strategy Mapping